 SAN DIEGO, March 12, 2021 PRNewswire -- Inhibrx, Inc. Nasdaq: INBX, a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105. Mark Lappe, Inhibrxs CEO commented, 2020 was a transformative year for Inhibrx. 